ICE Bioscience Posters

Download

Signal Transducer and Activator of Transcription 6 (STAT6) is a central mediator of IL‑4/IL‑13 signaling, and its dysregulation contributes to asthma, atopic dermatitis, fibrosis, and other immune‑driven diseases. With STAT6 therapeutics such as KT‑621 and REX‑8756 advancing clinically, there is growing demand for platforms that generate precise, translationally relevant data.

ICE Biosciences has developed a comprehensive, end‑to‑end workflow for STAT6 inhibitor and PROTAC discovery, built on our integrated target- ed protein degradation (TPD) platform and fully compatible with high‑throughput screening (HTS). Orthogonal biochemical and biophysical assays, including dual‑injection SPR for binding‑site resolution, establish robust target engagement. Cellular assays extend this to degradation, employing WB, FACS, and HiBiT readouts. To enhance translational relevance, functional assays using human primary samples, such as cytokine measurements in blood and smooth muscle cells, are developed. Selectivity and cross‑species profiling ensure confidence across models, while in‑depth MoA studies provide mechanistic clarity. Beyond molecular and cellular characterization, the workflow integrates comprehensive safety evaluation with advancing in  studies. By uniting biochemical precision, cellular function, and pharmacological depth, this platform delivers actionable insights to accelerate next‑generation STAT6 therapeutics for autoimmune and inflammatory diseases.